Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Participation Type:

HIVR4P Home

HIVR4P 2016 is made possible in part by the generous support of the American people through 1 R13 AI122959-01 from the National Institute of Allergy and Infectious Diseases (NIAID), and from the United States Agency for International Development (USAID). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services or USAID; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 sessions: 1 to 20 of 20
Symposium 01: Vaccine-Induced Humoral Immunity
Initiation of Neutralizing Antibody B Cell Lineages by HIV Vaccine Candidates
Barton Haynes
Duke University, United States
Protection from Rectal SHIV Infection Induced by Mucosal Vaccination with a Replication-competent VSV-HIV Chimera Delivering Env Trimers
Christopher Parks
The International AIDS Vaccine Initiative, United States
Towards a Global HIV Vaccine: (Pre)-Clinical Evaluation of Prime-Boost Regimens Using Ad26 and MVA with Mosaic Antigens and Soluble Gp140 Proteins
Hanneke Schuitemaker
Janssen Vaccine and Prevention, Netherlands
Defining Correlates of Protective Humoral Immunity against HIV
Galit Alter
Ragon Institute of MGH, MIT and Harvard, United States
from HIV Research for Prevention 2016 on 18 October 2016 15:30-17:00
Symposium 02: The Role of Mucosal Barriers and Targets in HIV Acquisition
A Central Role for α4β7+ CD4+ T Cells in HIV Transmission and Pathogenesis
Claudia Cicala
National Institute of Allergy and Infectious Diseases, NIH, United States
Effects of Sex Hormones and Vaginal Microbiota on the Cervicovaginal Mucosal Barrier
Janneke van de Wijgert
University of Liverpool, United Kingdom
Tissue Compartmentalization of Human Immune Responses
Donna Farber
Columbia University Medical Center, United States
Vaginal Bacteria modulate HIV Pre-exposure Prophylaxis Efficacy in Women
Adam Burgener
Public Health Agency of Canada, Canada
from HIV Research for Prevention 2016 on 18 October 2016 15:30-17:00
Symposium 03: Choosing ARVs for Prevention: Ensuring and Measuring Effective Tissue Delivery
Location, Location, Location: Pharmacology and Tissue Delivery of ARVs
Angela Kashuba
University of North Carolina, United States
Issues with Administration Route as It Relates to Participant Preference, Dosing Strategies, and Coverage Around Times at Risk
Julie Fox
United Kingdom
Pharmacologic Approaches to Assess Adherence
Peter Anderson
University of Colorado, Denver, United States
Linking PK and PD: Choosing Drugs and Predicting Clinical Outcomes Using Data from Explant Models, Animal Models
Jim Turpin
Division of AIDS, NIAID, NIH, United States
from HIV Research for Prevention 2016 on 18 October 2016 15:30-17:00
Symposium 04: Adolescents: Bodies, Brains and Behaviors
Research Gaps in Understanding Sex Steroid Hormones and Biological and Immunological Features that May Impact Susceptibility to HIV
Sharon L. Achilles
University of Pittsburgh, United States
Promoting Resilience: Understanding Implications of Psychological Development and Decision-making
Susan Rosenthal
Columbia University Medical Center, United States
How to Talk to Me about Sex
Two Youth from Chicago - Kortez Davis and Sydney Roberson
United States
What Interventions Are Suitable for Adolescents?
Chewe Luo
UNICEF, United States
from HIV Research for Prevention 2016 on 18 October 2016 15:30-17:00
Symposium 05: Using ARVs and Antibodies for Long-Acting Prevention
One Person's Challenge Is Another Person's Opportunity: Antibody Mediated Prevention Is a Milestone Opportunity
Larry Corey
Fred Hutchinson Cancer Research Center, United States
Pipeline for Long-Acting Passive Prophylaxis: How and When Will We Choose?
Nina Russell
Bill and Melinda Gates Foundation
AAV and Other Novel Antibody Delivery Platforms
Frances Priddy
International AIDS Vaccine Initiative, United States
Engineering HIV Antibodies for Potency, Breadth and Half-life
John Mascola
National Institute of Allergy and Infectious Diseases, NIH, United States
from HIV Research for Prevention 2016 on 19 October 2016 15:30-17:00
Symposium 06: Effective Cellular Immune Reponses
Role of T Cells in Controlling HIV Infection
Andrew McMichael
University of Oxford, United Kingdom
Risk of HIV Acquisition Correlates Inversely with T Cell Polyfunctionality in Vaccine Efficacy Trials
Nicole Frahm
Fred Hutchinson Cancer Research Center, United States
Development of a Cytomegalovirus-based HIV Vaccine
Louis Picker
Oregon Health & Science University, United States
ADCC Immunity against HIV
Stephen Kent
University of Melbourne, Australia
from HIV Research for Prevention 2016 on 19 October 2016 15:30-17:00
Symposium 07: Entering the Dark Zone: Germinal Centers in Immune Response
Role of Adjuvants in Enhancing Durability of HIV Vaccine Responses by Inducing Potent Germinal Centers and Plasma Cell Responses
Sudhir Kasturi
Emory University, United States
The Many Flavors of Vaccine-Induced CD4 T Cell Responses
Hendrik Streeck
Institute for HIV Research, Germany
B Cell Follicle Sanctuary Permits Persistent Productive SIV Infection in Elite Controllers: Implications for HIV Cure
Afam Okoye
Oregon Health & Science University, United States
Selection Dynamics in the Germinal Center during Antibody Affinity Maturation
Alexander Gitlin
Rockefeller University, United States
from HIV Research for Prevention 2016 on 20 October 2016 08:30-10:00
Symposium 08: Envelope Structure and Broadly Neutralizing Antibodies
Structural Dynamics of HIV Env Glycoproteins: A Link between Structural, Functional, and Phenotypic Variation among Isolates
Kelly Lee
University of Washington, United States
The HIV Glycan Shield as a Target for Broadly Neutralizing Antibodies
Katie Doores
King's College London, United Kingdom
Immunogenicity of Multiple SOSIP Trimers in Different Animal Species
John Moore
Weill Medical College, United States
Broadly Neutralizing Antibody Lineages and Precursors
Penny Moore
University of the Witwatersrand, South Africa
from HIV Research for Prevention 2016 on 20 October 2016 08:30-10:00
Symposium 01: Overcoming Barriers to Broadly Neutralizing Antibody Induction
Prevention Strategies Based on HIV-1 Neutralizing Antibodies
John Mascola
National Institutes of Health, Bethesda, MD, United States
Broadly Neutralizing Antibody Responses in HIV-1 Infection: Insights from a Large Cohort and from Individuals
Elise Landais
IAVI Neutralizing Antibody Center at The Scripps Research Institute, La Jolla, CA, United States
HIV Envelope Interactions with the Progenitor BCRs of Narrow and Broadly Neutralizing Antibodies
Leonidas Stamatatos
Seattle Biomedical Research Institute, Seattle, WA, United States
HIV-1 Mimicry of Host Antigens: Hiding in Plain Sight to Evade Immunity
Garnett Kelsoe
Duke University, Durham, NC, United States
from HIV Research for Prevention 2014 on 28 October 2014 15:30-17:00
Symposium 02: Advances in Animal Models
Non-Human Primate Models for New Prevention Strategies of HIV Transmission
Roger Le Grand
CEA, Fontenay-aux-Roses, France
How Mice to Monkeys Inform Human B Cell Repertoire Responses
Gunilla Karlsson Hedestam
Karolinska Institutet, Stockholm, Sweden
Prevention Studies in Nonhuman Primate Models
Jeffrey Lifson
National Institutes of Health, Bethesda, MD, United States
The Role of Humanized Mice in Advancing HIV Vaccine and Eradication Studies
Todd Allen
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, United States
from HIV Research for Prevention 2014 on 28 October 2014 15:30-17:00
Symposium 03: Treatment as Prevention: The Promise and the Perils
No Time to Lose - The Importance of Early HIV Infection
Kimberly Powers
The University of North Carolina at Chapel Hill, Chapel Hill, NC, United States
A Tale of Four Treatment-as-Prevention Trials in Africa
Frank Tanser
University of KwaZulu-Natal, Mtubatuba, South Africa
Treatment as Prevention - How Can We Predict Success?
Deenan Pillay
Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Mtubatuba, South Africa
TasP Promises...But What Is The Reality?
Valerie Delpech
Public Health England, London, United Kingdom
from HIV Research for Prevention 2014 on 28 October 2014 15:30-17:00
Symposium 04: Building Combination Prevention Trials
Building Combination Prevention: Trial Designs
Helen Weiss
London School of Hygiene & Tropical Medicine, London, United Kingdom
Combination Prevention: From Trials to Implementation
Sinead Delany-Moretlwe
University of the Witwatersrand, Johannesburg, South Africa
The Role of Mathematical Modeling to Design, Conduct, Interpret and Replicate HIV Prevention Trials
Marie-Claude Boily
Imperial College London, London, United Kingdom
Scalable Adherence Interventions
Terrence Blaschke
Bill and Melinda Gates Foundation, Seattle, WA, United States
from HIV Research for Prevention 2014 on 28 October 2014 15:30-17:00
Symposium 05: The Role of Structure Based Design in Vaccine Development and Immunoprophylaxis
Structure-Based Design of Improved Antibodies for HIV-1 Treatment or Prevention
Pamela Bjorkman
California Institute of Technology, Pasadena, CA, United States
The Stucture of the Glycan Shield of HIV
Max Crispin
University of Oxford, Oxford, United Kingdom
Structure-Based Stabilization of the Prefusion Closed HIV-1 Env Trimer
Peter Kwong
National Institutes of Health, Bethesda, MD, United States
Reductionist Vaccine Design to Induce Broadly Neutralizing Antibodies against HIV
William Schief
The Scripps Research Institute, La Jolla, CA, United States
from HIV Research for Prevention 2014 on 29 October 2014 15:30-17:00
Symposium 06: Harnessing Antibody Effector Functions
Evaluating HIV-1 Vaccine Induced Antibody Effector Function to Advance Vaccine Candidates
Georgia Tomaras
Duke University, Durham, NC, United States
A Systems Serology Approach to Vaccination
Margie Ackerman
Dartmouth College, Hanover, NH, United States
Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques
Sampa Santra
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States
Combating Cell-Cell Transmission of HIV with Antibodies - Slaying the Trojan Horse?
Stephen Kent
University of Melbourne, Melbourne, Australia
from HIV Research for Prevention 2014 on 29 October 2014 15:30-17:00
Symposium 07: Novel Formulations and Sustained Delivery of Antiretrovirals
Injectable and Implantable Antiretroviral Strategies for HIV Prevention
Ian McGowan
University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
Intravaginal Rings for HIV Prevention in Women
Thesla Palanee-Phillips
Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
Novel On-Demand Vaginal Microbicide Formulations: Tablets and Films
Jill Schwartz
CONRAD Eastern Virginia Medical School, Arlington, VA, United States
Nanotechnology for Drug Delivery
Kim Woodrow
University of Washington, Seattle, WA, United States
from HIV Research for Prevention 2014 on 29 October 2014 15:30-17:00
Symposium 08: Mucosal Barriers to Infection
Upper Female Genital Tract and Defining Safety
Ruth Greenblatt
University of California San Francisco, San Francisco, CA, United States
Behavioral and Biological Factors Affecting HIV Acquisition in Women
Douglas Kwon
Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital and Harvard Medical School, Cambridge, MA, United States
Mechanisms of HIV-1 Restriction and Dissemination Mediated by Intestinal Mucosal Myeloid Cells
Gabriella Scarlatti
San Raffaele Scientific Institute, Milan, Italy
Rectal Microbicide Development: An Update
Ross Cranston
University of Pittsburgh, Pittsburgh, PA, United States
from HIV Research for Prevention 2014 on 30 October 2014 15:30-17:00
Symposium 09: Sustaining Durability of Responses
Clinical Translation of HIV Protein-Expressing Cytomegalovirus Vectors
Louis Picker
Oregon Health & Science University, Beaverton, OR, United States
Antibody Persistence and T Cell Balance: Two Key Factors Confronting HIV Vaccine Development
George Lewis
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States
Adjuvants and Durability of Vaccine-Induced Immunity
Marguerite Koutsoukos
GlaxoSmithKline, Rixensart, Belgium
Integrase Defective Lentiviral Vectors for Induction of Persistent and Functional Immune Responses
Andrea Cara
Istituto Superiore di Sanità, Rome, Italy
from HIV Research for Prevention 2014 on 30 October 2014 15:30-17:00
Symposium 10: Challenges of Biomedical HIV Prevention Trials
HIV Prevention Trials: Their Successes and Failures
Jeanne Marrazzo
University of Washington, Seattle, WA, United States
Modifiers of PrEP Efficacy: Co-Infections, Sex, Hormones and Microbiome
Betsy Herold
Albert Einstein College of Medicine, Bronx, NY, United States
Enrolling Adolescents in HIV Vaccine Trials: Will We Be Ready?
Ann Strode
University of KwaZulu-Natal, Pietermaritzburg, South Africa
Why Context Matters in Understanding the Challenges to Clinical Trials
Jonathan Stadler
Wits Reproductive Health & HIV Institute, Johannesburg, South Africa
from HIV Research for Prevention 2014 on 31 October 2014 08:30-10:00
Symposium 11: Emerging Areas in Immunity
Systems Vaccinology: Enabling Rational Vaccine Design with Systems Biology
Bali Pulendran
Emory Vaccine Center, Atlanta, GA, United States
Resident Memory CD8 T Cells: Quantity, Location, and Function
David Masopust
University of Minnesota, Minneapolis, MN, United States
Universal, MHC-E Restricted CD8+ T Cells Participate in RhCMV Vaccine Vector-Induced Protection Against SIV
Jonah Sacha
Oregon Health & Science University, Beaverton, OR, United States
Cooperativity of HIV-specific Cytolytic CD4 T-cells and CD8 T-cells in Control of HIV Viremia
Susan Johnson
US Military HIV Research Program, Silver Spring, MD, United States
from HIV Research for Prevention 2014 on 31 October 2014 08:30-10:00
Symposium 12: Differential Use of Antibodies in Prevention
Update on Clinical Development of VRC01 and Second Generation Neutralizing CD4 Binding Site-Specific Monoclonal Antibodies
Barney Graham
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
Engineering Bispecific Antibodies for HIV Prevention
Neal Padte
Aaron Diamond AIDS Research Center, New York, NY, United States
HIV Cell-To-Cell Spread and Host Countermeasures
Olivier Schwartz
Institut Pasteur, Paris, France
from HIV Research for Prevention 2014 on 31 October 2014 08:30-10:00
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 sessions: 1 to 20 of 20